Could Mounjaro’s New Heart Benefit Unlock the Next Growth Phase for Lilly?

insidermonkey.com · 2026-09-08

Eli Lilly and Company’s (NYSE:LLY) Mounjaro has already become a major growth driver in diabetes treatment, and its latest FDA approval could strengthen that position by expanding what physicians can...

TickrTrends take: Mounjaro's emerging cardiovascular benefits could expand the drug's addressable market beyond diabetes treatment, potentially supporting higher revenue projections that may justify premium valuations for Lilly. Given TickrTrends' current undervalued assessment, investors should monitor clinical trial outcomes and regulatory approval timelines for heart-related indications, as successful expansion could narrow or eliminate any valuation discount. The development represents a key catalyst that could materially shift growth expectations for the Healthcare sector company.

Read the full story at insidermonkey.com →